BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors
- 1 September 2011
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 1 (4), 352-365
- https://doi.org/10.1158/2159-8290.cd-11-0106
Abstract
Cancers with specific genetic mutations are susceptible to selective kinase inhibitors. However, there is a wide spectrum of benefit among cancers harboring the same sensitizing genetic mutations. Herein, we measured apoptotic rates among cell lines sharing the same driver oncogene following treatment with the corresponding kinase inhibitor. There was a wide range of kinase inhibitor-induced apoptosis despite comparable inhibition of the target and associated downstream signaling pathways. Surprisingly, pretreatment RNA levels of the BH3-only pro-apoptotic BIM strongly predicted the capacity of EGFR, HER2, and PI3K inhibitors to induce apoptosis in EGFR-mutant, HER2-amplified, and PIK3CA-mutant cancers, respectively, but BIM levels did not predict responsiveness to standard chemotherapies. Furthermore, BIM RNA levels in EGFR-mutant lung cancer specimens predicted response and duration of clinical benefit from EGFR inhibitors. These findings suggest assessment of BIM levels in treatment-naïve tumor biopsies may indicate the degree of benefit from single-agent kinase inhibitors in multiple oncogene-addiction paradigms. Significance: In several oncogene-addiction paradigms, assessment of BIM RNA levels identifies those cancers that fail to have substantial apoptotic responses to kinase inhibitors. BIM RNA levels may be assessed in diagnostic cancer specimens to predict which patients will receive less benefit from single-agent kinase inhibitors. Cancer Discovery: 1(4); 352–65. ©2011 AACR. Read the Commentary on this article by Yoshida and Haura, p. 289 This article is highlighted in the In This Issue feature, p. 275Other Versions
This publication has 50 references indexed in Scilit:
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaThe New England Journal of Medicine, 2010
- Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicineEMBO Molecular Medicine, 2010
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLCCancer Cell, 2010
- Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II studyBritish Journal of Cancer, 2009
- PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cellsOncogene, 2009
- PI3K‐dependent cross‐talk interactions converge with Ras as quantifiable inputs integrated by ErkMolecular Systems Biology, 2009
- BAX activation is initiated at a novel interaction siteNature, 2008
- Colorectal cancer cells with the BRAFV600E mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIMOncogene, 2008
- Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytesNature Immunology, 2008
- Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol‐3 kinase pathways in non‐small cell lung cancer cellsInternational Journal of Cancer, 2005